touchIMMUNOLOGY coverage of EULAR 2025:
The 2025 European Alliance of Associations for Rheumatology (EULAR) Congress brought together leading rheumatologists, immunologists, and allied healthcare professionals from across Europe and beyond. Running from June 11–14 in Barcelona, the conference showcased the latest advances in immune-mediated musculoskeletal and systemic diseases, including groundbreaking clinical trials, novel biologic therapies, and emerging precision‑medicine strategies.
touchIMMUNOLOGY is proud to offer you in‑depth coverage from EULAR 2025, featuring exclusive interviews with top researchers and clinicians who shared their insights on optimizing patient care through immunological innovations. Our expert‑led content dives into key sessions on CAR T-cell therapy, long-term data, biosimilars, and patient reported outcomes, designed to keep you at the forefront of rheumatology and immunology practice. Stay tuned for engaging, insightful conversations that build on EULAR’s cutting‑edge science.
#EULAR2025 Sonelokimab Shows Promise in Improving PROs for Psoriatic Arthritis: Phase II ARGO Trial.
Laure Gossec
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis.
Dinesh Khanna
Bimekizumab Shows Comparable One-Year Efficacy in Male and Female axSpA Patients in Phase III BE MOBILE Trials.
Marina Magrey
RGB-19 Matches Tocilizumab in Efficacy and Safety: Promising Phase III Data from RA Biosimilar Trial.
Ernest Choy
This content has been developed independently by Touch Medical Media for touchIMMUNOLOGY. It is not affiliated with the European Alliance of Associations for Rheumatology (EULAR). Views expressed in each interview are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Cite: Inside EULAR 2025: Breakthroughs and Expert Perspectives in Rheumatology. touchIMMUNOLOGY. 4 July 2025.
Editor:Â Victoria Smith, Senior Content Editor.
Disclosures: This short article was prepared by touchIMMUNOLOGY. touchIMMUNOLOGY utilize AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No fees or funding were associated with its publication.
SIGN UP to TouchIMMUNOLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
